Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Summary

Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.

Eligibility

Inclusion Criteria:

* Adults aged 18 to 100 years.
* A histologically confirmed diagnosis of hepatocellular carcinoma.
* A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma.
* Healthy volunteers without known liver disease or malignancy.
* Received standard diagnostic and staging procedures as per local guidelines
* Availability of blood or other biospecimens.
* Ability to provide written informed consent.

Exclusion Criteria:

* Lack of or inability to provide informed consent
* History of other active malignancies within the past 5 years
* Previous liver transplantation
* Severe systemic infection or inflammatory disease at the time of enrollment
* Inadequate sample quality or quantity

Conditions4

Locations1 site

Find trials near these locations

Browse More Trials